drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, genetically engineered CAR T-cell therapy that dual-targets CD19 and CD22 to deplete malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize CD19 and CD22 on B cells. Upon antigen engagement, the CAR T cells activate, proliferate, release cytokines, and kill malignant B cells via cytotoxic mechanisms (perforin/granzyme), leading to depletion of CD19+/CD22+ tumor cells and on-target B-cell aplasia.
drug_name
KQ-2002 (CD19/CD22 CAR T cells)
nct_id_drug_ref
NCT06445803